Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  New England Journal of Medicine

• Publication date

  2001-05-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJM200105103441904PMID 11346808
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.

  2000cited by this paper
• Sequential parathyroid hormone/alendronate therapy for osteoporosis--robbing Peter to pay Paul?

  2000cited by this paper
• Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

  1999cited by this paper
• Mice, Estrogen, and Postmenopausal Osteoporosis

  1999cited by this paper
• Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

  1999cited by this paper
• Survival after the diagnosis of hyperparathyroidism: a population-based study.

  1998cited by this paper
• Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.

  1998cited by this paper
• Comparative calibration without a gold standard.

  1997cited by this paper
• Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older.

  1997cited by this paper
• Vitamin D Supplementation and Fracture Incidence in Elderly Persons

  1996cited by this paper
• Dual X‐ray absorptiometry quality control: Comparison of visual examination and process‐control charts

  1996cited by this paper
• Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

  1996cited by this paper
• Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial.

  1995cited by this paper
• Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

  1995cited by this paper
• Vertebral fracture assessment using a semiquantitative technique

  1993cited by this paper
• Anabolic actions of parathyroid hormone on bone.

  1993cited by this paper
• Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone

  1992cited by this paper
• Annual injection of vitamin D and fractures of aged bones

  1992cited by this paper
• Vitamin D3 and calcium to prevent hip fractures in elderly women.

  1992cited by this paper
• Treatment of postmenopausal osteoporosis with calcitriol or calcium.

  1992cited by this paper
• Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen

  1992cited by this paper
• Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients.

  1991cited by this paper
• Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.

  1990cited by this paper
• Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.

  1990cited by this paper
• Calcitriol treatment is not effective in postmenopausal osteoporosis.

  1989cited by this paper
• Increased risk of malignant diseases after surgery for primary hyperparathyroidism. A nationwide cohort study.

  1988cited by this paper
• Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds.

  1983cited by this paper
• Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration.

  1982cited by this paper
• Prevention of spinal osteoporosis in oophorectomised women.

  1980cited by this paper

• Systematic Review of Secondary Prevention Interventions and Approaches for Osteoporosis Management in Older People With Hip Fracture.

  2026cites this paper
• PTH induced osteoblast Slit3 to decrease aberrant sensory innervation in degenerated vertebral endplates to relieve low back pain in mice

  2026cites this paper
• Biologics for bone regeneration: advances in cell, protein, gene, and mRNA therapies

  2026cites this paper
• Selective deletion of the membrane-bound isoform of CSF1 in vivo augments the anabolic response to PTH without impairing bone resorption

  2026cites this paper
• Improvements in bone quality by parathyroid hormone treatment are enhanced in the Nmp4 knockout mouse model.

  2026cites this paper
• Targeted drug repurposing in medication-related osteonecrosis of the jaw: a review of teriparatide and pentoxifylline/α-tocopherol protocols

  2026cites this paper
• Clarifying clinically treatment-naive status for osteoporosis patients.

  2026cites this paper
• Ostéoporose

  2026cites this paper
• Teriparatide enhances vertebral bone quality: Quantitative analysis using the VBQ score in lumbar fusion patients.

  2026cites this paper
• Guía de Práctica Clínica multidisciplinaria para la osteoporosis en Colombia: recomendaciones basadas en la evidencia y adaptadas al contexto nacional

  2026cites this paper
• Irisin, Sclerostin, and Inflammatory Axis: Implication in Bone‐Muscle Wasting Diseases

  2026cites this paper
• Evaluation of Pulsed Current Iontophoresis for Enhancing the Transdermal Absorption of the Osteoporosis Drug Teriparatide

  2026cites this paper
• Real-world evidence indicates romosozumab use is associated with a greater reduction in osteoporotic fractures than PTH (1–34) analogs in women

  2026cites this paper
• Effects of teriparatide on hip structure and bone microarchitecture in women with anorexia nervosa: a placebo-controlled randomized trial.

  2026cites this paper
• Research Status and Hot Spot Visualization Analysis of Osteoporosis from 2014 to 2025

  2025cites this paper
• Management of osteoporosis in Parkinson's disease: A scoping review.

  2025cites this paper
• Optimizing Bone Health in the Treatment of Lumbar Spondylolisthesis.

  2025cites this paper
• The cellular effect of intermittent PTH treatment on bone remodeling and modeling in humans—a histomorphometry centered scoping review

  2025cites this paper
• Treatment-related changes in total hip bone mineral density are applicable to trials of varied study designs and to drugs with differing mechanisms of action: meta-regression results from the FNIH-ASBMR SABRE study

  2025cites this paper
• The 2024 UK clinical guideline for the prevention and treatment of osteoporosis

  2025influential citation
• Myeloma bone disease: A constant problem in the changing landscape of myeloma management

  2025cites this paper
• An Injectable Antioxidant Parathyroid Hormone Related Supramolecular Peptide Nanofiber Hydrogel for Repairing Osteoporotic Bone Defects.

  2025cites this paper
• Caveolin‐1 Regulates Parathyroid Hormone (PTH)‐Related Protein (PTHrP) Actions on PTH Receptor Type 1 in Bone Cells

  2025cites this paper
• Rethinking Osteoporosis Drugs: Can We Simultaneously Address Sarcopenia?

  2025cites this paper
• Parathyroid hormone receptor agonists in the management of osteoporosis

  2025influential citation
• Lifetime follow-up of an adult patient with pediatric-onset hypophosphatasia complicated with advanced chronic kidney disease

  2025cites this paper
• Advances in strontium-releasing biomaterials for bone repair.

  2025cites this paper
• Proceedings of the 2025 Santa Fe Bone Symposium: Current concepts in the care of patients with osteoporosis, parathyroid disorders, and rare bone diseases.

  2025cites this paper
• Comparative Bone Histomorphometry Effects of Combined Denosumab and Teriparatide versus Monotherapy in Postmenopausal Women with Osteoporosis: A Randomized Controlled Trial.

  2025cites this paper
• Adherence and persistence of daily and twice-weekly teriparatide treatment in postmenopausal women with high-risk of fracture.

  2025cites this paper
• Conservative Treatment with Teriparatide Versus Vertebroplasty for Acute Osteoporotic Vertebral Compression Fractures: A Meta-Analysis

  2025cites this paper
• PTH/PTHrP analogues as osteoanabolic treatment in patients with osteoporosis.

  2025cites this paper
• Bone Health Management in Men Commencing Androgen Deprivation Therapy for Prostate Cancer and Women Commencing Anti‐Oestrogen Therapy for Breast Cancer

  2025cites this paper
• Reverse engineering Frost's mechanostat model in mouse tibia: Insights from combined PTH and mechanical loading.

  2025cites this paper
• FABP4 inhibition suppresses bone resorption and protects against postmenopausal osteoporosis in ovariectomized mice

  2025cites this paper
• TERIPARATIDE IN SEQUENTAL TREATMENT OF OSTEOPOROSIS IN A PATIENT WITH SPINAL MUSCULAR ATROPHY: A CASE REPORT AND LITERATURE REVIEW

  2025cites this paper
• Bone in Parathyroid Diseases Revisited: Evidence From Epidemiological, Surgical and New Drug Outcomes

  2025cites this paper
• Phytoestrogens as Potential Anti-Osteoporosis Nutraceuticals: Major Sources and Mechanism(s) of Action.

  2025cites this paper
• First‐line treatment of osteoporosis with osteoanabolic therapy: a new opportunity

  2025cites this paper
• Ostéoporose : pourquoi quand et avec quel(s) médicament(s) traiter ? Comment la prévenir ?

  2025cites this paper
• Gut, bone, and muscle: the triad of osteosarcopenia in inflammatory bowel disease

  2025cites this paper
• The Role of Osteoporosis Agents in Enhancing Spinal Fusion

  2025cites this paper
• Comparative efficacy of teriparatide and bisphosphonates or denosumab vs. teriparatide monotherapy in osteoporosis: a meta-analysis

  2025cites this paper
• Fragility of Evidence for the Efficacy of Anti-Fracture Medications

  2025cites this paper
• Combination of Pilose Antler Extract and Hydroxytyrosol Enhances Bone Mineral Density in Both Animals and Postmenopausal Women

  2025cites this paper
• Artificial intelligence for predicting the risk of bone fragility fractures in osteoporosis

  2025cites this paper
• Strontium-Loaded Titanium and Systemic Teriparatide Synergistically Enhance Osteogenesis and Osseointegration in an Osteoporotic Rabbit Model.

  2025cites this paper
• Nucleic acid aptamers in orthopedic diseases: promising therapeutic agents for bone disorders

  2025cites this paper
• Timing optimization of teriparatide dosing for postmenopausal osteoporosis: a randomized controlled trial

  2025cites this paper
• Bisphosphonates in the Management of Patients with Postmenopausal Osteoporosis; Back to the Future

  2025cites this paper
• Optimizing type H vessels formation via short fibers 3D scaffolds with maintaining redox homeostasis for osteoporotic bone remodeling

  2025cites this paper
• Advances in the management of osteoporosis

  2025cites this paper
• Osteoporosis Epidemiology, Diagnosis, and Management Across Race and Ethnicity in the United States.

  2025cites this paper
• Advances in PTH-based Medicines.

  2025cites this paper
• Structure-Encoded Location Biased Signaling in a Class B GPCR: Focus on the PTH Type 1 Receptor.

  2025cites this paper
• Sequential Treatment for Osteoporosis After Teriparatide: A Real-Life Long-Term Comparison Between Zoledronic Acid and Denosumab

  2025cites this paper
• Effect of rhPTH(1-34) and alendronate on the treatment of type 2 diabetic bone disease

  2025cites this paper
• Impact of standard versus cyclic teriparatide and denosumab treatment on trabecular bone score: a post-hoc analysis of a randomized clinical trial

  2025cites this paper
• Mitochondrial β-oxidation of adipose-derived fatty acids by osteoblasts fuels parathyroid hormone–induced bone formation

  2025influential citation
• One-year bone mineral density gains with anti-osteoporotic medications and clinical factors associated with non-BMD gainers

  2025cites this paper
• SAT-763 A Case of Parathyroid Crisis with EKG Changes Mimicking ST Elevation Myocardial Infarct

  2025cites this paper
• [Sequence treatment of postmenopausal osteoporosis].

  2025cites this paper
• Evaluation of Peri-Implant Bone Repair in Ovariectomized Rats Submitted to the Implant Placement Functionalized with Anti-Sclerostin

  2025cites this paper
• Artificial intelligence in anti-obesity drug discovery: unlocking next-generation therapeutics.

  2025cites this paper
• Long-term impact of teriparatide on bone mineral density, trabecular bone score, and fracture risk relative to total hip T-score: A two-decade, registry-based cohort study.

  2025cites this paper
• In Vivo quantification of 4D modeling and remodeling in trabecular and cortical bone microstructure

  2025cites this paper
• Cystic fibrosis-related bone disease: an update on screening, diagnosis, and treatment

  2025cites this paper
• Navigating nephropathy and nephrotoxicity: understanding pathophysiology unveiling clinical manifestations, and exploring treatment approaches

  2025cites this paper
• Comprehensive Review of Osteogenesis Imperfecta: Current Treatments and Future Innovations

  2025cites this paper
• Evolving strategies for osteoporosis management in postmenopausal women: From tradition to innovation

  2025cites this paper
• Treatment failure in osteoporosis: who will experience a new Fracture? TAILOR a retrospective study

  2025cites this paper
• PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis

  2025influential citation
• The local pulsatile parathyroid hormone delivery system induces the osteogenic differentiation of dental pulp mesenchymal stem cells to reconstruct mandibular defects

  2025cites this paper
• Vitamin D and calcium supplementation in women undergoing pharmacological management for postmenopausal osteoporosis: a level I of evidence systematic review

  2025cites this paper
• Sequential and Long-term Therapy for Osteoporosis

  2025cites this paper
• Sequential therapy following teriparatide treatment in patients at high risk of osteoporotic patients

  2025cites this paper
• Teriparatide-induced Sever Persistent Hypercalcemia in an Osteoporotic Patient: A Case Report and Literature Review

  2025cites this paper
• PTH pre-treatment prior to tibial mechanical loading improves their synergistic anabolic effects in mice.

  2025cites this paper
• A Random Study of Comparing the Efficacy of Antiosteoporosis Therapy at Different Time Points Combined With Oblique Lateral Interbody Fusion in the Treatment of Lumbar Degenerative Disease Patients Complicated With Osteoporosis

  2025cites this paper
• Viridicatol from the Deep‐Sea‐Derived Fungus Alleviates Bone Loss by Targeting the Wnt/SHN3 Pathway

  2025cites this paper
• Treatment Considerations for Severe Osteoporosis in Older Adults

  2025cites this paper
• The utility of photon-counting CT localizer radiograph in bone densitometry

  2025cites this paper
• Bone-building osteoporosis therapies and the menopause practitioner.

  2025cites this paper
• Progress in oral biomaterials for the treatment of metabolic bone diseases

  2025cites this paper
• National guidelines for diagnosis and treatment of osteoporosis in Slovakia

  2025cites this paper
• Impacts of Prior Anti-Osteoporosis Treatments on Sequential Denosumab Responses in BMD Changes Among Postmenopausal Osteoporosis Women in East China: Real-World Data Analysis

  2025cites this paper
• Crosstalk between kidney and bones: New perspective for modulating osteoporosis.

  2025cites this paper
• Comparative analysis of teriparatide and calcium supplementation in post-surgery fracture healing among osteoporotic patients

  2025cites this paper
• Deciphering the gut microbiome’s metabolic code: pathways to bone health and novel therapeutic avenues

  2025cites this paper
• Medical Management of Osteoporosis: Updates and Future Directions

  2025cites this paper
• Renal dysfunction and its influence on osteoporosis treatment outcomes: a critical review of recent findings

  2025cites this paper
• Prolonged hypercalcemia induced by teriparatide: a case report and literature review

  2025cites this paper
• Effect of recombinant human parathyroid hormone and zoledronic acid on osteoblast gene expression using multifaceted approach: An in vitro study

  2025cites this paper
• A Phase 3 Multicenter, Double‐Blind Study Comparing Efficacy, Safety, Immunogenicity, and Pharmacokinetics of Alkem's Biosimilar Teriparatide Versus Reference Teriparatide in Postmenopausal Osteoporosis

  2025cites this paper
• Targeting SIRT3 to regulate mitophagy-dependent ferroptosis for preventing glucocorticoid-induced osteoporosis

  2025cites this paper
• Uric Acid in Primary Hyperparathyroidism: Marker, Consequence, or Bystander?

  2025cites this paper
• Structural insights into GPCR signaling activated by peptide ligands: from molecular mechanism to therapeutic application

  2025cites this paper
• Bone Anabolic Treatment in Older Subjects: A Narrative Review

  2025cites this paper
• Blockade of Gi Signaling Enhances the Anabolic Effect of Parathyroid Hormone in Female Mice

  2025cites this paper
• Osteoporosis and Rheumatoid Arthritis: Mechanisms Underlying Osteoclast Differentiation and Activation or Factors Associated with Hip Fractures

  2025cites this paper